Akari Therapeutics (NASDAQ:AKTX) Announces Earnings Results, Misses Estimates By $686.67 EPS

Akari Therapeutics (NASDAQ:AKTX) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($686.67), reports.

Akari Therapeutics Stock Performance

Shares of Akari Therapeutics stock traded up $13.13 during midday trading on Friday, hitting $18.27. The company had a trading volume of 32,951,741 shares, compared to its average volume of 417,685. The company has a 50 day moving average of $5.37 and a 200 day moving average of $10.53. Akari Therapeutics has a 52-week low of $3.02 and a 52-week high of $56.80.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AKTX shares. Maxim Group downgraded shares of Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright upped their target price on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $89.00.

More Akari Therapeutics News

Here are the key news stories impacting Akari Therapeutics this week:

• Positive Sentiment: Akari reported breakthrough preclinical data showing AKTX-101 worked synergistically with KRAS inhibition in pancreatic cancer models, boosting investor optimism about its lead ADC program. Article Title
• Positive Sentiment: Market commentary highlighted the stock’s surge after the cancer-data release, with some traders pointing to possible upside if the platform continues to show promise. Article Title
• Neutral Sentiment: Akari announced a $5.5 million private placement offering to fund development of AKTX-101, providing near-term cash but also signaling dilution risk. Article Title
• Neutral Sentiment: The company also announced an ADS ratio change and reverse split, a corporate action that can alter the share structure and often contributes to trading volatility. Article Title
• Negative Sentiment: Akari’s latest quarterly results missed expectations by a wide margin, underscoring that the company remains highly speculative and financially challenged. Article Title
• Negative Sentiment: Trading in AKTX was halted multiple times for LULD pauses, reflecting extreme intraday volatility as investors reacted to the news flow. Article Title

Institutional Trading of Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.